These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 22087606

  • 1. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy.
    Frost SH, Bäck T, Chouin N, Jensen H, Hultborn R, Jacobsson L, Lindegren S.
    Cancer Biother Radiopharm; 2011 Dec; 26(6):727-36. PubMed ID: 22087606
    [Abstract] [Full Text] [Related]

  • 2. 211At radioimmunotherapy of subcutaneous human ovarian cancer xenografts: evaluation of relative biologic effectiveness of an alpha-emitter in vivo.
    Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, Jacobsson L.
    J Nucl Med; 2005 Dec; 46(12):2061-7. PubMed ID: 16330571
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.
    J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
    [Abstract] [Full Text] [Related]

  • 4. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity.
    Elgqvist J, Andersson H, Bäck T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    Nucl Med Biol; 2006 Nov; 33(8):1065-72. PubMed ID: 17127181
    [Abstract] [Full Text] [Related]

  • 5. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.
    Frost SH, Bäck T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, Jensen H, Albertsson P, Lindegren S.
    Cancer Biother Radiopharm; 2013 Mar; 28(2):108-14. PubMed ID: 23230896
    [Abstract] [Full Text] [Related]

  • 6. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.
    Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, Warnhammar E, Jacobsson L.
    J Nucl Med; 2005 Mar; 46(3):464-71. PubMed ID: 15750160
    [Abstract] [Full Text] [Related]

  • 7. In vitro evaluation of avidin antibody pretargeting using 211At-labeled and biotinylated poly-L-lysine as effector molecule.
    Frost SH, Jensen H, Lindegren S.
    Cancer; 2010 Feb 15; 116(4 Suppl):1101-10. PubMed ID: 20127953
    [Abstract] [Full Text] [Related]

  • 8. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.
    J Nucl Med; 2009 Jul 15; 50(7):1153-60. PubMed ID: 19525452
    [Abstract] [Full Text] [Related]

  • 9. (211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers.
    Lindegren S, Karlsson B, Jacobsson L, Andersson H, Hultborn R, Skarnemark G.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3873S-9S. PubMed ID: 14506185
    [Abstract] [Full Text] [Related]

  • 10. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
    Elgqvist J, Andersson H, Bernhardt P, Bäck T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, Jacobsson L.
    Int J Radiat Oncol Biol Phys; 2006 Nov 15; 66(4):1228-37. PubMed ID: 17145538
    [Abstract] [Full Text] [Related]

  • 11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.
    Cancer Res; 1999 Jun 01; 59(11):2635-43. PubMed ID: 10363986
    [Abstract] [Full Text] [Related]

  • 12. Absorbed Doses and Risk Estimates of (211)At-MX35 F(ab')2 in Intraperitoneal Therapy of Ovarian Cancer Patients.
    Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P.
    Int J Radiat Oncol Biol Phys; 2015 Nov 01; 93(3):569-76. PubMed ID: 26460999
    [Abstract] [Full Text] [Related]

  • 13. Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.
    Bäck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, Jacobsson L.
    Cancer Biother Radiopharm; 2009 Dec 01; 24(6):649-58. PubMed ID: 20025544
    [Abstract] [Full Text] [Related]

  • 14. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab')2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival.
    Bäck T, Chouin N, Lindegren S, Kahu H, Jensen H, Albertsson P, Palm S.
    J Nucl Med; 2017 Apr 01; 58(4):598-604. PubMed ID: 27688477
    [Abstract] [Full Text] [Related]

  • 15. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.
    Clin Cancer Res; 1999 Oct 01; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [Abstract] [Full Text] [Related]

  • 16. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
    Postema EJ, Börjesson PK, Buijs WC, Roos JC, Marres HA, Boerman OC, de Bree R, Lang M, Munzert G, van Dongen GA, Oyen WJ.
    J Nucl Med; 2003 Oct 01; 44(10):1690-9. PubMed ID: 14530488
    [Abstract] [Full Text] [Related]

  • 17. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model.
    Gustafsson AM, Bäck T, Elgqvist J, Jacobsson L, Hultborn R, Albertsson P, Morgenstern A, Bruchertseifer F, Jensen H, Lindegren S.
    Nucl Med Biol; 2012 Jan 01; 39(1):15-22. PubMed ID: 21958859
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
    Andersson H, Elgqvist J, Horvath G, Hultborn R, Jacobsson L, Jensen H, Karlsson B, Lindegren S, Palm S.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
    [Abstract] [Full Text] [Related]

  • 20. Antibody fragments in tumor pretargeting. Evaluation of biotinylated Fab' colocalization with recombinant streptavidin and avidin.
    Wilbur DS, Hamlin DK, Vessella RL, Stray JE, Buhler KR, Stayton PS, Klumb LA, Pathare PM, Weerawarna SA.
    Bioconjug Chem; 1996 Sep 01; 7(6):689-702. PubMed ID: 8950488
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.